About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Current Search
Report Type
Organization
Disposition
Year
Month
Found 6951 record(s)
Req # A-2019-001880
All records related to how allocations through the First Nations Infrastructure fund are calculated with respect to funding for fire safety and infrastructure operations from January 1, 2010 to February 14, 2020.Organization: Health Canada
February 2020
Req # A-2019-001961
Internal correspondence (director-level and above), briefing materials related to M-174 (National Suicide Prevention Action Plan) from April 12, 2018 to February 26, 2020.Organization: Health Canada
February 2020
Req # A-2018-001847
Adverse Reaction Report (AER). Report numbers: E2B_1459859, E2B_1868158, E2B_1608785, E2B_1749489, E2B_1756985, E2B_1488673, E2B_1465304, E2B_1569944, E2B_1799808, E2B_2022012, E2B_1553204, E2B_1831642, E2B_1959239.Organization: Health Canada
February 2020
Req # A-2019-000101
Adverse Reaction Report (AER) for PANTOPRAZOLE MAGNESIUM. Report numbers: 718285, 720360, E2B_02142492, E2B_02151677, E2B_02164185, E2B_02186484, E2B_02211397, E2B_02252769.Organization: Health Canada
February 2020
Req # A-2019-000385
Adverse Reaction Report (AER) for HYDROXYCHLOROQUINE SULFATE. Report numbers: E2B_01681346, E2B_01747187, E2B_01774476, E2B_01726431, E2B_01777645, E2B_01671894, E2B_01747195, E2B_01659269, E2B_01657868, E2B_01661946, E2B_01657837, E2B_01745892, E2B_01781414, E2B_01771308, E2B_01780405, E2B_01775952, E2B_01741504, E2B_01772029, E2B_01789057, E2B_01789105, E2B_01743562, E2B_01744632, E2B_01751963, E2B_01708681, E2B_01700264, E2B_01707830, E2B_01738858, E2B_01710429, E2B_01813210.Organization: Health Canada
February 2020
Req # A-2019-000686
Adverse Reaction Report (AER). Report numbers: 718338, E2B_0052879, E2B_01310244, E2B_01829888, E2B_01833928, E2B_0190288, E2B_01958767, E2B_020101.Organization: Health Canada
February 2020
Req # A-2019-000691
Adverse Reaction Report (AER) for Celexa® (citalopram) and Cipralex® (escitalopram). Report numbers: E2B_02191135, E2B_02156070, E2B_02202443, E2B_02199275, E2B_02208247, 000720318, E2B_02210061, E2B_02208764, E2B_02246786, E2B_02204578, E2B_02254370, E2B_02231371, E2B_02231364, E2B_02242620, E2B_02256718, E2B_02231588, E2B_02311624, E2B_02286278, E2B_02275467, E2B_02275458, E2B_02306882, E2B_02484493, E2B_02306884.Organization: Health Canada
February 2020
Req # A-2019-000849
Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 19-109786-731.Organization: Health Canada
February 2020
Req # A-2019-000994
Adverse Reaction Report (AER). Report numbers: E2B_02574051, E2B_02574070, E2B_02574081, E2B_02574082, E2B_02575254.Organization: Health Canada
February 2020
Req # A-2019-001069
Adverse Reaction Report (AER). Report numbers: E2B_02445480, E2B_02284781, E2B_02275215, E2B_01735918, E2B_01896745, 000719053, 000719140, 000719936, E2B_02470140, 000725829, E2B_02545002, E2B_02256718, E2B_02252691.Organization: Health Canada
February 2020